Virtual Biotech

How 37,000 AI agents collaborate to transform drug discovery

The assumption that one engineer equals one AI agent is already outdated. At Stanford, James Zou's team has scaled past that model, building a virtual biotech where 37,000 specialized agents collaborate like a real company. The results speak for themselves: the system designed a drug that Merck later independently validated, earning FDA breakthrough status. For developers, the lesson isn't about building smarter single agents, it's about designing environments where thousands can work together. That's a shift worth exploring, especially as orchestration becomes the real bottleneck.